Jump to content

Search the Community

Showing results for tags 'awards'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • WELCOME NEW MEMBERS!
    • INTRODUCE YOURSELF!
  • STORIES OF SURVIVORSHIP
    • SHARE YOUR LUNG CANCER STORY
  • DISCUSSION FORUMS
    • GENERAL
    • LC SURVIVORS
    • NSCLC GROUP
    • SCLC GROUP
    • US VETERANS
    • CAREGIVER RESOURCE CENTER
  • TREATMENT FORUMS
    • CHEMOTHERAPY
    • IMMUNOTHERAPY
    • RADIATION
    • SURGERY
    • SUPPORTIVE CARE
  • LUNG CANCER NAVIGATOR
    • LUNG CANCER NAVIGATOR
  • NEWS / ADVOCACY
    • LUNG CANCER IN THE NEWS
    • ADVOCACY
  • LIVING WELL
    • HEALTHY LIVING / RECIPES
    • HOPE
    • JUST FOR FUN
  • SUPPORT
    • SUPPORT RESOURCES
  • GRIEF
    • GRIEF
  • TERMS OF USE
    • FEATURES AND SUPPORT

Blogs

  • An Advocates Perspective
  • Cheryncp123's Blog
  • Stay The Course
  • Lung Cancer Stories
  • Spree
  • Volunteer Voices
  • Caregivers Connection
  • Stage IV Treatment With S.B.R.T.
  • Susan Cornett
  • Robin S
  • Lung Cancer & Health Insurance: Tips on managing the mayhem.
  • Daze of My Life by Ken Lourie
  • CommUNITY Connection
  • Heather Smith
  • Lisa Haines
  • Veteran's Oprions
  • Cancer: holding his hand until his last breath
  • A Healthy Place
  • Lenny Blue
  • The Roscopal Effect
  • Ro
  • Sharron P
  • Loi ich suc khoe cua qua chi tu
  • Shanesga
  • Facts are stubborn things, but statistics are pliable

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Joined

  • Start

    End


Group


First name


Last name


City


Province or district (if non-US)


Postal code


Country


Interests

Found 2 results

  1. LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, announced today the recipients of its 2018 Career Development Awards (CDA) for lung cancer research. These coveted awards fund critical lung cancer research projects and offer the recipients world-class mentorship by LUNGevity’s prestigious Scientific Advisory Board. “We are excited to support these exceptionally talented new investigators. Interestingly, all three of these projects involve liquid biopsy-based approaches to detecting and optimizing treatment of lung cancer. These new projects may define new avenues for applying liquid biopsies in the clinical setting,” notes Charles Rudin, MD, PhD, Professor and Chief, Thoracic Oncology Service, at Memorial Sloan Kettering Cancer Center and chair of LUNGevity’s Scientific Advisory Board. “We believe that this outstanding group of awardees will help make progress in improving outcomes for lung cancer patients.” LUNGevity is proud to support the following 2018 Career Development Award researchers: Kellie Smith, PhD, Johns Hopkins School of Medicine, Immunometabolic T cell profiling as a prognostic liquid biopsy in non-small cell lung cancer. Dr. Smith’s research group will work to develop a liquid biopsy that predicts advanced-stage non-small cell lung cancer patient responses to combination immunotherapy regimens. Jeffrey Thompson, MD, University of Pennsylvania, Development of markers to predict response to immunotherapy in NSCLC. Dr. Thompson’s laboratory is working to develop blood-based tests to identify individuals most likely to respond to immunotherapy with minimum side effects, helping to ensure customized immunotherapies for advanced-stage non-small cell lung cancer patients. Edwin Yau, MD, PhD, Roswell Park Cancer Institute, Lung cancer detection by CRISPR-based detection of circulating tumor DNA. Dr. Yau’s team is developing a quick and cost-effective blood test for early detection of lung cancer that will complement CT screening. “By funding young investigators, LUNGevity keeps outstanding scientists, still early in their careers, in the lung cancer space. We work closely with these researchers with the hope of seeing them become the next generation of scientific superstars,” says Andrea Ferris, President and CEO of LUNGevity. “The CDA program encourages their continued development in the field of lung cancer research to grow a strong pipeline of dedicated lung cancer researchers.” Under the stewardship of LUNGevity’s Scientific Advisory Board, a group of 21 prominent scientists and researchers, LUNGevity ensures that grants are awarded to those researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as for extending and improving lives of lung cancer survivors. LUNGevity is the only lung cancer organization with a programmatic focus on early detection and a robust Career Development Award Program. Our researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The foundation’s overall research program, including CDA awards, is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. LUNGevity’s Scientific Research Program is supported by individual donors, the American Lung Association, Bristol-Myers Squibb, The Thomas G. Labrecque Foundation, Upstage Lung Cancer, and the Schmidt Legacy Foundation. Read the full press release.
  2. LUNGevity Foundation's Career Development Awards (CDA) for lung cancer research fund critical lung cancer research projects and offer the recipients world-class mentorship by LUNGevity’s prestigious Scientific Advisory Board. “LUNGevity created the CDAs to identify outstanding scientists early in their careers and encourage their continued development in the field of lung cancer research to grow a strong pipeline of dedicated lung cancer researchers,” says Charles Rudin, MD, PhD, Professor and Chief, Thoracic Oncology Service, at Memorial Sloan Kettering Cancer Center and chair of LUNGevity’s Scientific Advisory Board. “We work closely with these researchers with the hope of seeing them become the next generation of scientific superstars.” LUNGevity is proud to support the following researchers its 2017 Career Development Awards: Mehmet Altan, MD, The University of Texas MD Anderson Cancer Center, Identification of predictive markers of toxicity to immunotherapy. Dr. Altan will work to develop a way to predict which patients are most likely to develop serious side effects from some types of immunotherapy – these side effects can limit use of the treatments. Once patients can be flagged as high-risk for tissue damage, measures can be taken to limit the tissue damage proactively; patients may then experience better outcomes with their immunotherapy. Valsamo Anagnostou, MD, PhD, Johns Hopkins University, Dynamics of neoantigen landscape during immunotherapy in lung cancer. Dr. Anagnostou will leverage an existing clinical trial to discover why some patients become resistant to immunotherapy and to get a handle on how to help them overcome the resistance. Zofia Piotrowska, MD, Massachusetts General Hospital, Overcoming heterogeneity and resistance in EGFR-mutant NSCLC. Dr. Piotrowska intends to uncover the reason a subset of lung cancer patients develop resistance to their best option for treatment: a third-generation EGFR-blocking tyrosine kinase inhibitor drug. In addition, she will study a new combination of drugs in a clinical trial that may help patients who develop this type of drug resistance. “We have seen a lot of great progress in treating lung cancer, and we still need to better understand how lung cancer develops resistance to drugs, and why some patients experience side effects from treatment,” notes Upal Basu Roy, PhD, MPH, director of LUNGevity’s translational science research program. “Our funding this year’s group of awardees will help make progress in facing these challenges and continue to improve outcomes for lung cancer patients.” Each of these prestigious three-year awards is for $100,000 per year, renewable in the second and third years based on research progress. Awardees serve as non-voting members of LUNGevity’s distinguished Scientific Advisory Board for the terms of their awards. Awardees are mentored by senior lung cancer experts at their own institutions as well as by experts from the Scientific Advisory Board. Under the guidance of LUNGevity’s Scientific Advisory Board, a group of 21 prominent scientists and researchers, LUNGevity ensures that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives for lung cancer survivors. LUNGevity is the only lung cancer organization with a programmatic focus on early detection and a robust Career Development Award Program. Our researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The foundation’s overall research program, including CDA awards, is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. LUNGevity’s Scientific Research Program is supported by the American Lung Association, Bristol-Myers Squibb, Genentech, The Thomas G. Labrecque Foundation, Upstage Lung Cancer, and individual donors. Read the full press release.
×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.